These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 9549348)

  • 1. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
    Sugiyama I; Sadzuka Y
    Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
    Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
    Nam SM; Kim HS; Ahn WS; Park YS
    Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
    Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
    J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD; Dougherty G; Harasym TO; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
    Han HD; Lee A; Hwang T; Song CK; Seong H; Hyun J; Shin BC
    J Control Release; 2007 Jul; 120(3):161-8. PubMed ID: 17524514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
    Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
    J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dose on the distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes.
    Sadzuka Y; Nakai S; Miyagishima A; Nozawa Y; Hirota S
    J Drug Target; 1995; 3(1):31-7. PubMed ID: 7655818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possibility of active targeting to tumor tissues with liposomes.
    Maruyama K; Ishida O; Takizawa T; Moribe K
    Adv Drug Deliv Rev; 1999 Nov; 40(1-2):89-102. PubMed ID: 10837782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.